Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors

Nuwellis (NUWE) has provided an update.

Nuwellis, Inc. has marked a significant milestone with its inaugural commercial sale of QUELIMMUNE™ Therapy to Cincinnati Children’s Hospital, a promising treatment for pediatric patients afflicted by severe immune system-induced inflammation. This achievement comes as part of the company’s exclusive distribution agreement in the U.S. with the therapy’s developer, SeaStar. While this news offers potential growth opportunities for Nuwellis, the company cautions investors against relying solely on forward-looking statements due to the inherent uncertainties of the market and regulatory environment.

Find detailed analytics on NUWE stock on TipRanks’ Stock Analysis page.